Kimia Biosciences AGM approves increased borrowing limits
- Kimia Biosciences held its 33rd AGM virtually on September 28, 2026
- Members approved special resolutions to increase borrowing limits and create asset charges
- Board expanded with three new director appointments including two independents
- Financial statements for FY26 were adopted during the meeting
*this image is generated using AI for illustrative purposes only.
Kimia Biosciences Limited held its 33rd Annual General Meeting on September 28, 2026, approving key resolutions to expand its financial flexibility. Members voted to increase the company's borrowing limit under Section 180(1)(c) of the Companies Act, 2013, signaling a potential shift in capital structure strategy.
The virtual meeting, conducted via Video Conferencing/Other Audio Visual Means, was chaired by Sameer Goel, Managing Director and CEO. The proceedings included the adoption of audited financial statements for FY26 and several appointments to the board. A shareholder speaker expressed satisfaction with the management's transparency and business continuity efforts.
Key resolutions approved
The members passed both ordinary and special resolutions covering governance changes and financial authorizations. The special resolutions are particularly notable for granting the board broader powers regarding debt and asset encumbrance.
| Item | Type | Particulars of Resolution |
|---|---|---|
| 1 | Ordinary | Adoption of Audited Financial Statements for FY26 |
| 2 | Ordinary | Re-appointment of Sameer Goel as Director |
| 3 | Ordinary | Approval of Cost Auditor remuneration for FY26 |
| 4 | Ordinary | Appointment of Amulya Kumar Nayak as Director |
| 5 | Ordinary | Appointment of Reema Goyal as Independent Woman Director |
| 6 | Ordinary | Appointment of Avinash Prabhat as Independent Director |
| 7 | Special | Increase in borrowing limit under Section 180(1)(c) |
| 8 | Special | Creation of mortgage/charge on movable/immovable properties |
| 9 | Special | Approval of loans/investments/guarantees under Section 185 |
| 10 | Special | Increase in limits for investments/loans/guarantees under Section 186 |
Governance and leadership updates
The meeting facilitated significant changes in the board composition. Sameer Goel was re-appointed in place of himself, retiring by rotation. New directors Amulya Kumar Nayak, Reema Goyal, and Avinash Prabhat were appointed, with Goyal and Prabhat joining as Independent Non-Executive Directors. This expansion of the independent director pool aims to strengthen oversight mechanisms.
Strategic implications of financial mandates
The approval of special resolutions to increase borrowing limits and create charges on assets indicates a preparatory step for potential capital expenditure or operational funding needs. By securing these authorizations in advance, the board retains the flexibility to leverage its balance sheet without requiring immediate shareholder intervention for specific debt instruments. The simultaneous approval of limits under Sections 185 and 186 further suggests a structured approach to inter-corporate transactions and investments.
Voting results and the scrutinizer's report will be submitted to BSE Limited and hosted on the company website within the prescribed timeline under SEBI regulations.
Historical Stock Returns for Kimia Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.21% | +7.01% | +15.37% | +10.51% | -16.71% | 0.0% |
What specific capital expenditure projects or operational expansions will the increased borrowing limit primarily fund?
How might the new debt capacity impact Kimia Biosciences' credit rating and cost of capital in upcoming fiscal quarters?
Will the appointment of new independent directors lead to tangible changes in the company's ESG or governance reporting standards?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
